



(51) International Patent Classification:

A61K 9/50 (2006.01) A61P 11/16 (2006.01)
A61K 31/485 (2006.01)

(21) International Application Number:

PCT/IB2011/054767

(22) International Filing Date:

25 October 2011 (25.10.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/406,752 26 October 2010 (26.10.2010) US

(71) Applicant (for all designated States except US): **AL-PHARMA PHARMACEUTICALS, LLC** [US/US];
400 Crossing Boulevard, Bridgewater, New Jersey 08807 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LAMSON, Michael J.** [US/US]; Pfizer Inc., 4000 Centregreen Way Suite 300, Cary, North Carolina 27513 (US). **VEERAINDAR, Goli** [US/US]; Pfizer Inc., 4000 Centregreen Way Suite 3000, Cary, North Carolina 27513 (US).

(74) Agent: **BENSON, Gregg C.**; Pfizer Inc., Eastern Point Road, Groton, Connecticut 06340 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

[Continued on next page]

(54) Title: FORMULATIONS AND METHODS FOR ATTENUATING RESPIRATORY DEPRESSION INDUCED BY OPIOID OVERDOSE

FIGURE 1



(57) Abstract: The invention relates to compositions and methods for attenuating opioid induced respiratory depression. Such compositions comprise opioid and sequestered opioid antagonists in a multi-particulate dosage formulation.



Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*